Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
University of Giessen · Klinikum Leverkusen · +10 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,485
total citations
- FWCI
- 90.03
- Percentile
- 100%
- References
- 29
Citations per year
Authors
20Topics & keywords
Topics
Keywords
- Medicine
- Bendamustine
- Rituximab
- Mantle cell lymphoma
- Vincristine
- Internal medicine
- CHOP
- Prednisone
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.